BDBM572149 US11447504, Example 2::US11447504, Example 3::US11447504, Example 4::US11478451, Example 4::rac-4-chloro-1,3-dimethyl-7-[3-(naphthalen-1-yloxy)propyl]-1,10,11,12,13,15-hexahydropyrazolo[4′,3′:9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic Acid

SMILES Cc1nn(C)c2COCCCCn3c(C(O)=O)c(CCCOc4cccc5ccccc45)c4ccc(Cl)c(-c12)c34

InChI Key InChIKey=PPCSRTPOKGWSIX-UHFFFAOYSA-N

Data  14 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 14 hits for monomerid = 572149   

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572149(US11447504, Example 2 | US11447504, Example 3 | US...)
Affinity DataIC50:  1.60nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBcl-2-like protein 1 [1-212]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572149(US11447504, Example 2 | US11447504, Example 3 | US...)
Affinity DataIC50: >2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-XL and the BH3 domain of Bad (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2/Bcl2-associated agonist of cell death [103-127,M117N](Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572149(US11447504, Example 2 | US11447504, Example 3 | US...)
Affinity DataIC50: >2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572149(US11447504, Example 2 | US11447504, Example 3 | US...)
Affinity DataIC50:  1.10nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBcl-2-like protein 1 [1-212]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572149(US11447504, Example 2 | US11447504, Example 3 | US...)
Affinity DataIC50: >2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-XL and the BH3 domain of Bad (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2/Bcl2-associated agonist of cell death [103-127,M117N](Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572149(US11447504, Example 2 | US11447504, Example 3 | US...)
Affinity DataIC50: >2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572149(US11447504, Example 2 | US11447504, Example 3 | US...)
Affinity DataIC50:  38nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBcl-2-like protein 1 [1-212]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572149(US11447504, Example 2 | US11447504, Example 3 | US...)
Affinity DataIC50:  1.60E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-XL and the BH3 domain of Bad (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2/Bcl2-associated agonist of cell death [103-127,M117N](Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572149(US11447504, Example 2 | US11447504, Example 3 | US...)
Affinity DataIC50: >2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572149(US11447504, Example 2 | US11447504, Example 3 | US...)
Affinity DataIC50:  1.60nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572149(US11447504, Example 2 | US11447504, Example 3 | US...)
Affinity DataIC50:  1.10nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572149(US11447504, Example 2 | US11447504, Example 3 | US...)
Affinity DataIC50: >2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBcl-2-like protein 1 [1-212]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572149(US11447504, Example 2 | US11447504, Example 3 | US...)
Affinity DataIC50: >2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-XL and the BH3 domain of Bad (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572149(US11447504, Example 2 | US11447504, Example 3 | US...)
Affinity DataIC50:  38nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent